Hormone replacement therapy, inflammation, and hemostasis in elderly women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 4, 1999, Pages 893-899

  Cushman, Mary ^a,f   Meilahn, Elaine N ^b   Psaty, Bruce M ^c   Kuller, Lewis H ^d   Dobs, Adrian S ^e   Tracy, Russell P ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Blood coagulation; Elderly; Hormone replacement therapy; Inflammation; Women

Indexed keywords

ALPHA1 GLYCOPROTEIN; ANTIPLASMIN; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; D DIMER; ESTROGEN; FIBRINOGEN; GESTAGEN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN;

AGED; ARTICLE; BLOOD CLOTTING; BODY MASS; CONTROLLED STUDY; CORONARY RISK; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0032893058     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.4.893     Document Type: Article

References (40)

1. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
2. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol. 1993;137:54-63.
3. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062-1071.
4. Psaty BN, Heckbert SR, Atkins D, Lemaitre RN, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154:1333-1339.
5. Sidney S, Petitti DB, Quesenbenry CP. Myocardial infarction and the use of estrogen and estrogen-progestin in postmenopausal women. Ann Intern Med. 1997;127:501-508.
6. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ. 1997;315:149-153.
7. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335: 453-461.
8. Hulley S, Grady D, Bush T, Furberg C, Herringlon D, Riggs B, Vittinghoff E, for the Heart, and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
9. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
10. Richards CD, Gauldie J. Role of cytokines in acute-phase response. In: Aggarwal BB, Puri RK, eds. Human Cytokines: Their Role in Disease and Therapy. Cambridge, Mass: Blackwell Science, Inc; 1995:253-269.
11. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis, and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
13. Ridker PM, Buring JE, Shin J, Matias M, Hennekens CH. A prospective study of C-reactive protein and risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
14. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilhan EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
15. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
16. Phillips A, Shaper A, Whincup P. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet. 1989;1434-1436.
17. Gillum RF, Makuc DM. Serum albumin, coronary heart disease, and death. Am Heart J. 1992;123:507-513.
18. Kuller L, Tracy R, Shaten J, Meilahn E. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-547.
19. Corti MC, Salive ME, Guralnik JM. Serum albumin and physical function as predictors of coronary heart disease mortality and incidence in older persons. J Clin Epidemiol. 1996;49:519-526.
20. Gandrille S, Aiach M. Albumin concentration influences fibrinolytic activity in plasma and purified systems. Fibrinolysis. 1990;4:225-232.
21. Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol. 1997;50:693-703.
22. Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, for the Cardiovascular Health Study Investigators. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1995; 15:1269-1279.
23. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemostas. 1992;68: 392-395.
24. Kroon U, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemostas. 1994;71:420-423.
25. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336: 683-690.
26. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Tracy RP, Weiler PG, CHS Research Group. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1:263-276.
27. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, Bush TL, for the CHS Collaborative Research Group. Associations of postmenopausal estrogen use with cardiovascular risk factors in older women. Circulation. 1993;88:2163-2171.
28. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5:270-277.
29. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995;5: 278-285.
30. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;42:264-270.
31. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52-58.
32. Declerck PJ, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res. 1990;10(Suppl):3-9.
33. Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost. 1987;58:1024-1029.
34. Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha-2-antiplasmin complex in human plasma - application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost. 1986;56: 124-127.
35. Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol. 1996; 143:159-166.
36. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol. 1997;17:1822-1829.
37. Song CS, Merkatz IR, Rifkind AB, Gillette PN, Kappas A. The influence of pregnancy and oral contraceptive steroids on the concentration of plasma proteins. Am J Obstet Gynecol. 1970;108:227-231.
38. Cushman M, Bovill EG, Psaty BM, Cornell E, Macy E, Kuller LH, Tracy RP. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 1996;16: 1163-1169.
39. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Circulation. 1998;18:1-6.
40. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-978.